论文部分内容阅读
目的研究乳腺癌患者激素受体(hormone receptor,HR)及人表皮生长因子受体-2基因(human epidermal growth factor receptor 2,HER-2)表达状况与ABO血型的关系,为揭示乳腺癌与ABO血型之间的关系提供科学依据。方法收集2013年1月至2016年4月于遂宁市中心医院就诊,行免疫组化(immunohistochemistry,IHC)测定并且血型报告可查的466例乳腺癌患者为研究对象,统计患者HR状态及HER-2基因表达情况。采用SPSS 20.0统计软件进行数据分析,计数资料的比较用χ~2检验。结果 466例患者的中位年龄为50岁(25~89岁),肿瘤分期为:Ⅰ期95例(20.4%),Ⅱ期250例(53.7%),Ⅲ期106例(22.7%),Ⅳ期15例(3.2%)。HR阴性157例(33.7%),HR阳性309例(66.3%),HER-2基因扩增型100例(21.5%),状态未知83例(17.8%),非扩增型283例(60.7%)。HR状态与ABO血型分布无相关性(χ~2=2.338,P=0.505),HER-2状态与ABO血型分布有相关性(χ~2=13.154,P=0.041),进一步两两比较结果提示,HER-2基因扩增状态与状态未知与A型、AB型血分布相关(χ~2=5.169,P=0.002)。结论乳腺癌IHC结果与ABO血型分布可能存在一定相关性。
Objective To study the relationship between the expression of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER-2) and the ABO blood group in patients with breast cancer. The relationship between blood type provides a scientific basis. Methods A total of 466 breast cancer patients from January 2013 to April 2016 in Suining Central Hospital for immunohistochemistry (IHC) and blood group report were included in the study. HR status and HER- 2 gene expression. SPSS 20.0 statistical software was used for data analysis, count data comparison with χ ~ 2 test. Results The median age of 466 patients was 50 years old (25-89 years old). The tumor staging was 95 cases (20.4%) in stage Ⅰ, 250 cases (53.7%) in stage Ⅱ and 106 cases (22.7%) in stage Ⅲ Period of 15 cases (3.2%). There were 157 cases of HR negative (33.7%), 309 cases of HR positive (66.3%), 100 cases (21.5%) of HER-2 amplification, 83 cases (17.8%) unknown and 283 cases (60.7% ). There was no correlation between HR status and ABO blood group distribution (χ ~ 2 = 2.338, P = 0.505). There was a correlation between HER-2 status and ABO blood group distribution (χ ~ 2 = 13.154, P = 0.041) The status and status of HER-2 gene amplification were not related to the type A and type AB blood distribution (χ ~ 2 = 5.169, P = 0.002). Conclusion IHC results of breast cancer may be related to ABO blood group distribution.